Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: A review

Inflammatory Bowel Diseases

Volumn 17, Issue 7, 2011, Pages 1603-1609

  Park, K T ^a,b   Bass, Dorsey ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b NONE   (United States)

Author keywords

cost effectiveness analysis; healthcare cost; inflammatory bowel disease

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE;

ANTIBIOTIC THERAPY; CLINICAL PRACTICE; COLON RESECTION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DIAGNOSTIC TEST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; ENTERITIS; EVIDENCE BASED PRACTICE; HEALTH CARE COST; HOSPITAL COST; HUMAN; IMMUNE DEFICIENCY; LIVER TOXICITY; OUTPATIENT CARE; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; INFLAMMATORY BOWEL DISEASES; UNITED STATES;

EID: 79958835184     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21488     Document Type: Review

References (56)

1. Loftus EV., Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517.
2. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007; 5: 1424-1429. (Pubitemid 350181588)
3. Sewell JL, Yee HF Jr, Inadomi JM., Hospitalizations are increasing among minority patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 204-207.
4. Longobardi T, Jacobs P, Bernstein CN., Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol. 2004; 99: 650-655. (Pubitemid 38607968)
5. Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008; 24: 319-328. (Pubitemid 351294380)
6. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. Occup Environ Med. 2008; 50: 1261-1272.
7. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008; 135: 1907-1913.
8. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Disease. 2010 [Epub ahead of print].
9. Odes S, Vardi H, Friger M, et al. European Collaborative Study on Inflammatory Bowel Disease. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131: 719-728. (Pubitemid 44307060)
10. Bernstein CN, Papineau N, Zajaczkowski J, et al. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000; 95: 677-683. (Pubitemid 30123901)
11. Hillson E, Dybicz S, Waters HC, et al. Health care expenditures in ulcerative colitis: the perspective of a self-insured employer. Occup Environ Med. 2008; 50: 969-977.
12. Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008; 14: 352-362. (Pubitemid 351890850)
13. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000; 95: 524-530. (Pubitemid 30106188)
14. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999; 117: 49-57. (Pubitemid 29297619)
15. Cohen RD, Waters HC, Tang B, et al. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008; 14: 1707-1714.
16. Levesque BG, Cipriano LE, Chang SL, et al. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. Clin Gastroenterol Hepatol. 2010; 8: 261-267.
17. Goldfarb NI, Pizzi LT, Fuhr JP Jr, et al. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Dis Manag. 2004; 7: 292-304. (Pubitemid 40111032)
18. Provenzale D, Wong JB, Onken JE, et al. Performing a cost-effectiveness analysis: surveillance of patients with ulcerative colitis. Am J Gastroenterol. 1998; 93: 872-880. (Pubitemid 29076969)
19. Provenzale D, Onken J., Surveillance issues in inflammatory bowel disease. Ulcerative colitis. J Clin Gastroenterol. 2001; 32: 99-105. (Pubitemid 32113237)
20. Rubenstein JH, Waljee AK, Jeter JM, et al. Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates. Am J Gastroenterol. 2009; 104: 2222-2232.
21. Shen B, Shermock KM, Fazio VW, et al. A cost-effectiveness analysis of diagnostic strategies for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol. 2003; 98: 2460-2467. (Pubitemid 37448757)
22. Parsi MA, Ellis JJ, Lashner BA., Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. J Clin Gastroenterol. 2008; 42: 799-805.
23. Available at
24. Nikfar S, Rahimi R, Rezaie A, et al. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009; 54: 1157-1170.
25. Mackowiak JI., A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis. Manag Care Interface. 2006; 19: 39-46,56.
26. Buckland A, Bodger K., The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 1287-1296.
27. Akobeng AK, Gardener E., Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2005; 1: CD003715.
28. Dubinsky MC, Reyes E, Ofman J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol. 2005; 100: 2239-2247.
29. Waljee AK, Joyce JC, Wang S, et al. Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines. Clin Gastroenterol Hepatol. 2010; 8: 143-150.
30. 2006 Drug topics, red book. Montvale, NJ: Medical Economics; 2006.
31. Ollendorf DA, Lidsky L., Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting. Am J Ther. 2006; 13: 502-506. (Pubitemid 44813679)
32. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549. (Pubitemid 34621118)
33. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
34. Thomas T, Cohen RD., Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Rev Gastroenterol Hepatol. 2007; 1: 101-112.
35. Irving PM, Gibson PR., Infliximab: getting the most for your money. J Gastroenterol Hepatol. 2007; 22: 1559-1561. (Pubitemid 47383337)
36. Cohen RD, Thomas T., Economics of the use of biologics in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2006; 35: 867-882. (Pubitemid 44791838)
37. Jaisson-Hot I, Flourié B, Descos L, et al. Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004; 20: 274-279. (Pubitemid 39079562)
38. Saro C, da la Coba C, Casado MA, et al. Resource use in patients with Crohn's disease treated with infliximab. Aliment Pharmacol Ther. 2007; 26: 1313-1323. (Pubitemid 350064013)
39. Lindsay J, Punekar YS, Morris J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008; 28: 76-87. (Pubitemid 351782815)
40. Tsai HH, Punekar YS, Morris J, et al. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008; 28: 1230-1239.
41. Arseneau KO, Cohn SM, Cominelli F, et al. Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology. 2001; 120: 1640-1656. (Pubitemid 32523483)
42. Condino AA, Fidanza S, Hoffenberg EJ., A home infliximab infusion program. J Pediatr Gastroenterol Nutr. 2005; 40: 67-69. (Pubitemid 40180060)
43. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65. (Pubitemid 46108762)
44. Wu EQ, Mulani PM, Yu AP, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008; 11: 820-829.
45. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009; 58: 492-500.
46. Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 1509-1520. (Pubitemid 350178810)
47. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics. 2009; 27: 609-621.
48. Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients' and physicians' perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis. 2009; 15: 581-588.
49. Nguyen GC, Frick KD, Dassopoulos T., Medical decision analysis for the management of unifocal, flat, low-grade dysplasia in ulcerative colitis. Gastrointest Endosc. 2009; 69: 1299-1310.
50. Swenson BR, Hollenbeak CS, Poritz LS, et al. Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization. Dis Colon Rectum. 2005; 48: 256-261. (Pubitemid 40576556)
51. Holubar SD, Long KH, Loftus EV Jr, et al. Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota. Dis Colon Rectum. 2009; 52: 1815-1823.
52. Higgins PD, Rubin DT, Kaulback K, et al. Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment Pharmacol Ther. 2009; 29: 247-257.
53. Kane S, Shaya F., Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci. 2008; 53: 1020-1024. (Pubitemid 351379831)
54. Longobardi T, Jacobs P, Bernstein CN., Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003; 98: 1064-1072. (Pubitemid 36733768)
55. Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99: 91-96. (Pubitemid 38679108)
56. Longobardi T, Jacobs P, Wu L, et al. Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol. 2003; 98: 844-849. (Pubitemid 36576312)